{
    "title": "Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents \u2013 assessment of adverse events in non\u2010randomised studies",
    "abstract": "Background Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non\u2010serious adverse events.    Objectives To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non\u2010randomised studies.    Search methods In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases and two trials registers. We also checked reference lists and contacted authors and pharmaceutical companies to identify additional studies.    Selection criteria We included non\u2010randomised study designs. These comprised comparative and non\u2010comparative cohort studies, patient\u2010control studies, patient reports/series and cross\u2010sectional studies of methylphenidate administered at any dosage or formulation. We also included methylphenidate groups from RCTs assessing methylphenidate versus other interventions for ADHD as well as data from follow\u2010up periods in RCTs. Participants had to have an ADHD diagnosis (from the 3rd to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders or the 9th or 10th edition of theInternational Classification of Diseases, with or without comorbid diagnoses. We required that at least 75% of participants had a normal intellectual capacity (intelligence quotient of more than 70 points) and were aged below 20 years. We excluded studies that used another ADHD drug as a co\u2010intervention.    Data collection and analysis Fourteen review authors selected studies independently. Two review authors assessed risk of bias independently using the ROBINS\u2010I tool for assessing risk of bias in non\u2010randomised studies of interventions. All review authors extracted data. We defined serious adverse events according to the International Committee of Harmonization as any lethal, life\u2010threatening or life\u2010changing event. We considered all other adverse events to be non\u2010serious adverse events and conducted meta\u2010analyses of data from comparative studies. We calculated meta\u2010analytic estimates of prevalence from non\u2010comparative cohorts studies and synthesised data from patient reports/series qualitatively. We investigated heterogeneity by conducting subgroup analyses, and we also conducted sensitivity analyses.    Main results We included a total of 260 studies: 7 comparative cohort studies, 6 of which compared 968 patients who were exposed to methylphenidate to 166 controls, and 1 which assessed 1224 patients that were exposed or not exposed to methylphenidate during different time periods; 4 patient\u2010control studies (53,192 exposed to methylphenidate and 19,906 controls); 177 non\u2010comparative cohort studies (2,207,751 participants); 2 cross\u2010sectional studies (96 participants) and 70 patient reports/series (206 participants). Participants' ages ranged from 3 years to 20 years. Risk of bias in the included comparative studies ranged from moderate to critical, with most studies showing critical risk of bias. We evaluated all non\u2010comparative studies at critical risk of bias. The GRADE quality rating of the evidence was very low.  Primary outcomes  In the comparative studies, methylphenidate increased the risk ratio (RR) of serious adverse events (RR 1.36, 95% confidence interval (CI) 1.17 to 1.57; 2 studies, 72,005 participants); any psychotic disorder (RR 1.36, 95% CI 1.17 to 1.57; 1 study, 71,771 participants); and arrhythmia (RR 1.61, 95% CI 1.48 to 1.74; 1 study, 1224 participants) compared to no intervention.  In the non\u2010comparative cohort studies, the proportion of participants on methylphenidate experiencing any serious adverse event was 1.20% (95% CI 0.70% to 2.00%; 50 studies, 162,422 participants). Withdrawal from methylphenidate due to any serious adverse events occurred in 1.20% (95% CI 0.60% to 2.30%; 7 studies, 1173 participants) and adverse events of unknown severity led to withdrawal in 7.30% of participants (95% CI 5.30% to 10.0%; 22 studies, 3708 participants).  Secondary outcomes  In the comparative studies, methylphenidate, compared to no intervention, increased the RR of insomnia and sleep problems (RR 2.58, 95% CI 1.24 to 5.34; 3 studies, 425 participants) and decreased appetite (RR 15.06, 95% CI 2.12 to 106.83; 1 study, 335 participants).  With non\u2010comparative cohort studies, the proportion of participants on methylphenidate with any non\u2010serious adverse events was 51.2% (95% CI 41.2% to 61.1%; 49 studies, 13,978 participants). These included difficulty falling asleep, 17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants); headache, 14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants); abdominal pain, 10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants); and decreased appetite, 31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants). Withdrawal of methylphenidate due to non\u2010serious adverse events occurred in 6.20% (95% CI 4.80% to 7.90%; 37 studies, 7142 participants), and 16.2% were withdrawn for unknown reasons (95% CI 13.0% to 19.9%; 57 studies, 8340 participants).    Authors' conclusions Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non\u2010serious adverse events in children and adolescents, which often lead to withdrawal of methylphenidate. Our certainty in the evidence is very low, and accordingly, it is not possible to accurately estimate the actual risk of adverse events. It might be higher than reported here.  Given the possible association between methylphenidate and the adverse events identified, it may be important to identify people who are most susceptible to adverse events. To do this we must undertake large\u2010scale, high\u2010quality RCTs, along with studies aimed at identifying responders and non\u2010responders.",
    "review_type": "Intervention",
    "doi": "https://doi.org/10.1002/14651858.CD012069.pub2",
    "review_id": "CD012069",
    "criteria": {
        "Types of studies": "We only included the following non\u2010randomised study designs (Higgins 2011). Comparative cohort studies. Here, the experimental group was children or adolescents with ADHD exposed to methylphenidate and the control group was comparable patients not exposed to methylphenidate.    Patient\u2010control studies. Here, the patient ('case') group was children or adolescents with ADHD exposed to methylphenidate, and the control group was comparable patients not exposed to methylphenidate.    Non\u2010comparative cohort studies. In this study type, children or adolescents with ADHD were exposed to methylphenidate with no control group. We also included the methylphenidate\u2010treated group from randomised clinical trials (RCTs) comparing methylphenidate versus other interventions for ADHD, as these trials were not included in our previous review of RCTs assessing methylphenidate versus placebo or no intervention (Storeb\u00f8 2015). In this way, we were able to expand our evidence base on adverse events during methylphenidate administration (as such groups are comparable to classic cohort studies), without double\u2010counting from RCTs assessing methylphenidate versus placebo or no intervention (Storeb\u00f8 2015). For assessment of adverse events in RCTs assessing methylphenidate versus placebo or no intervention, the reader is referred to our systematic review on that topic (Storeb\u00f8 2015).    Patient reports/series. This study type was formerly known and also described in our protocol as 'case\u2010studies' (Storeb\u00f8 2016).    Cross\u2010sectional studies. Comparative cohort studies. Here, the experimental group was children or adolescents with ADHD exposed to methylphenidate and the control group was comparable patients not exposed to methylphenidate. Patient\u2010control studies. Here, the patient ('case') group was children or adolescents with ADHD exposed to methylphenidate, and the control group was comparable patients not exposed to methylphenidate. Non\u2010comparative cohort studies. In this study type, children or adolescents with ADHD were exposed to methylphenidate with no control group. We also included the methylphenidate\u2010treated group from randomised clinical trials (RCTs) comparing methylphenidate versus other interventions for ADHD, as these trials were not included in our previous review of RCTs assessing methylphenidate versus placebo or no intervention (Storeb\u00f8 2015). In this way, we were able to expand our evidence base on adverse events during methylphenidate administration (as such groups are comparable to classic cohort studies), without double\u2010counting from RCTs assessing methylphenidate versus placebo or no intervention (Storeb\u00f8 2015). For assessment of adverse events in RCTs assessing methylphenidate versus placebo or no intervention, the reader is referred to our systematic review on that topic (Storeb\u00f8 2015). Patient reports/series. This study type was formerly known and also described in our protocol as 'case\u2010studies' (Storeb\u00f8 2016). Cross\u2010sectional studies. For a description of cohort, cross\u2010sectional, and patient\u2010control studies, see Table 1. Study design Description Cohort study An observational study in which a defined group with \u2265 1 samples of people (the cohort) is followed over time. The outcomes of people in subsets of this cohort might be compared, to examine people who were exposed or not exposed (or exposed at different levels) to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective (or historical) cohort study identifies participants from past records and follows them from the time of those records to the present. Because participants are not allocated by the investigator to different interventions or other exposures, adjusted analysis is usually required to minimise the influence of other factors (confounders). Patient\u2010control study A study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls), and which seeks to find associations between the outcome and prior exposure to particular risk factors. This design is particularly useful when the outcome is rare and when past exposure can be reliably measured. Patient\u2010control studies are usually but not always retrospective. Cross\u2010sectional study Studies in which the presence or absence of disease or other health\u2010related variables are determined for each member of the study population or in a representative sample at one particular time. This contrasts with cohort studies, which are followed over a period of time. Taken from the Cochrane Glossary. See Differences between protocol and review.",
        "Types of participants": "Children and adolescents with ADHD, with or without comorbid conditions. At least 75% of study participants were required to be aged 18 years or younger, and the mean age of the trial population had to be 18 years of age or younger. We also required that at least 75% of participants had a normal intellectual quotient (IQ > 70 points). See Differences between protocol and review. We accepted the following diagnoses of ADHD. A diagnosis of ADHD made according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) \u2010 3rd Edition (DSM\u2010III; APA 1980); 3rd Edition \u2010 Revised (DSM\u2010III\u2010R; APA 1987); 4th Edition (DSM\u2010IV; APA 1994); 4th Edition \u2010 Text Revision (DSM\u2010IV\u2010TR; APA 2000), or5th Edition (DSM\u20105; APA 2013).    A diagnosis of hyperkinetic disorders made in accordance with the International Classification of Diseases \u2010 9th Revision (ICD\u20109; WHO 1977) and\u201010th Revision (ICD\u201010; WHO 1992). A diagnosis of ADHD made according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) \u2010 3rd Edition (DSM\u2010III; APA 1980); 3rd Edition \u2010 Revised (DSM\u2010III\u2010R; APA 1987); 4th Edition (DSM\u2010IV; APA 1994); 4th Edition \u2010 Text Revision (DSM\u2010IV\u2010TR; APA 2000), or5th Edition (DSM\u20105; APA 2013). A diagnosis of hyperkinetic disorders made in accordance with the International Classification of Diseases \u2010 9th Revision (ICD\u20109; WHO 1977) and\u201010th Revision (ICD\u201010; WHO 1992).",
        "Types of interventions": "Methylphenidate administered at any dosage or formulation as part of any medical treatment regimen. In the comparative cohort studies and patient\u2010control studies, we included studies that compared cointerventions as long as the compared intervention groups received the same cointerventions. In the non\u2010comparative cohort studies, we allowed some types of comedication but not cointervention with another type of ADHD medication. See Differences between protocol and review.",
        "Types of outcome measures": "We defined the term 'adverse events' as any harm, adverse effect, or adverse drug reaction associated with methylphenidate. We defined 'withdrawals' as any participants withdrawn from methylphenidate medication. Serious adverse events. A serious adverse event is defined as any event that is fatal; life\u2010threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; or results in persistent or significant disability, or any event that requires intervention to prevent any of these outcomes in accordance with the Guideline for Good Clinical Practice E6(R1) (ICH 1996).    Withdrawal of methylphenidate due to serious adverse events.   Withdrawal of methylphenidate due to adverse events of unknown severity. Serious adverse events. A serious adverse event is defined as any event that is fatal; life\u2010threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; or results in persistent or significant disability, or any event that requires intervention to prevent any of these outcomes in accordance with the Guideline for Good Clinical Practice E6(R1) (ICH 1996). Withdrawal of methylphenidate due to serious adverse events. Withdrawal of methylphenidate due to adverse events of unknown severity. Non\u2010serious adverse events. All other adverse events, including but not confined to, the following common types of adverse events: cardiovascular, neurological, gastrointestinal, difficulty with sleep, and growth retardation in accordance with the Guideline for Good Clinical Practice E6(R1) (ICH 1996).    Withdrawal of methylphenidate due to non\u2010serious adverse events.   Withdrawal of methylphenidate for unknown reasons. Non\u2010serious adverse events. All other adverse events, including but not confined to, the following common types of adverse events: cardiovascular, neurological, gastrointestinal, difficulty with sleep, and growth retardation in accordance with the Guideline for Good Clinical Practice E6(R1) (ICH 1996). Withdrawal of methylphenidate due to non\u2010serious adverse events. Withdrawal of methylphenidate for unknown reasons. Adverse events were measured during treatment, at the end of treatment and at the longest follow\u2010up, using rating scales, spontaneous reports recorded by the investigators at regular interviews or visits, and physical examinations or para\u2010clinical examinations. We reported the primary and the secondary outcomes in summary of findings Table for the main comparison. See Differences between protocol and review.",
        "Primary outcomes": "Serious adverse events. A serious adverse event is defined as any event that is fatal; life\u2010threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; or results in persistent or significant disability, or any event that requires intervention to prevent any of these outcomes in accordance with the Guideline for Good Clinical Practice E6(R1) (ICH 1996).    Withdrawal of methylphenidate due to serious adverse events.   Withdrawal of methylphenidate due to adverse events of unknown severity.",
        "Secondary outcomes": "Non\u2010serious adverse events. All other adverse events, including but not confined to, the following common types of adverse events: cardiovascular, neurological, gastrointestinal, difficulty with sleep, and growth retardation in accordance with the Guideline for Good Clinical Practice E6(R1) (ICH 1996).    Withdrawal of methylphenidate due to non\u2010serious adverse events.   Withdrawal of methylphenidate for unknown reasons.    Adverse events were measured during treatment, at the end of treatment and at the longest follow\u2010up, using rating scales, spontaneous reports recorded by the investigators at regular interviews or visits, and physical examinations or para\u2010clinical examinations.  We reported the primary and the secondary outcomes in summary of findings Table for the main comparison.  See Differences between protocol and review."
    },
    "search_strategy": {
        "Appendix 1. Search strategies": "Cochrane Central Register of Controlled Trials (Central) in the Cochrane Library #1 MeSH descriptor: [Methylphenidate] explode all trees #2 Methylphenidate #3 Attenta #4 Biphentin #5 Calocain #6 Centedrin* #7 Concerta #8 Daytrana #9 Dexmethylphenidat* #10 Equasym #11 Focalin #12 Medikinet #13 Meridil #14 Metadate #15 Methyl phenidat* #16 Methyl phenidylacetat* #17 Methylfenid* #18 Methylin #19 Methylofenidan #20 Methylphenid* #21 Methyl phenidyl acetat* #22 Methypatch #23 Metilfenidato #24 Motiron #25 MPH #26 Penid #27 Phenidyl hydrochlorid* #28 Phenidylat* #29 Plimasin* #30 PMS\u2010Methylphenid* #31 Richter Works #32 Riphenidat* #33 Ritalin* #34 Rubifen #35 Stimdat* #36 Tsentedrin* #37 MeSH descriptor: [Child] explode all trees #38 MeSH descriptor: [Adolescent] explode all trees #39 MeSH descriptor: [Infant] explode all trees #40 (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*) #41 elmifiten or medikid or Omozin or Quazym or Tifinidat or Tranquilyn #42 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #41 #43 #37 or #38 or #39 or #40 #44 #42 and #43 #45 MeSH descriptor: [Attention Deficit and Disruptive Behavior Disorders] explode all trees #46 ADHD:ti,ab,kw #47 ADDH:ti,ab,kw #48 (ADHS):ti,ab,kw #49 (\"AD/HD\"):ti,ab,kw #50 ((attention* or behav*) near/3 (defic* or dysfunc* or disorder*)):ti,ab,kw #51 (impulsiv* or inattentiv* or inattention*):ti,ab,kw #52 ((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*)):ti,ab,kw #53 MeSH descriptor: [Hyperkinesis] explode all trees #54 (hyperkine*):ti,ab,kw #55 (minimal near/3 brain near/3 (disorder* or dysfunct* or damage*)):ti,ab,kw #56 (hyperactiv*):ti,ab,kw #57 #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 #58 #44 and #57    MEDLINE Ovid  Efficacy search  Block A: ADHD 1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14    Block B: Study design 16. randomized controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized controlled trials.mp. 19. random allocation.mp. 20. double blind method.mp. 21. single blind method.mp. 22. clinical trial.pt. 23. (clin$ adj25 trial$).ti,ab. 24. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).mp. 25. exp clinical trial/ 26. placebos.mp. 27. placebo$.ti,ab. 28. random$.ti,ab. 29. comparative study.mp. 30. evaluation studies as topic/ 31. exp clinical trials as topic/ 32. follow up studies.mp. 33. prospective studies.mp. 34. (control$ or prospectiv$ or volunteer$).ti,ab. 35. longitudinal.tw. 36. retrospective.tw. 37. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 38. exp Clinical Trials as Topic/ 39. exp Cohort Studies/ 40. exp Case\u2010Control Studies/ 41. \"case report*\".pt. 42. case control.tw. 43. (cohort adj (study or studies)).tw. 44. \"cohort analy*\".tw. 45. (observational adj (study or studies)).tw. 46. cross sectional.tw. 47. (follow up adj (study or studies)).tw. 48. (case* adj report*).tw. 49. (case* adj stud*).tw. 50. case reports.pt. 51. Cross\u2010Sectional Studies/ 52. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 53. 37 or 52 54. 15 and 53 [Block A AND Block B]    Block C: Methylphenidate 55. Methylphenidate.mp. or Methylphenidate/ 56. Attenta.mp. 57. Biphentin.mp. 58. Calocain.mp. 59. Centedrin*.mp. 60. Concerta.mp. 61. Daytrana.mp. 62. Dexmethylphenidat*.mp. 63. Equasym.mp. 64. Elmifiten.mp. 65. Focalin.mp. 66. Medikid.mp. 67. Medikinet.mp. 68. Meridil.mp. 69. Metadate.mp. 70. Methyl phenidat*.mp. 71. Methyl phenidylacetat*.mp. 72. Methylfenid*.mp. 73. Methylin.mp. 74. Methylofenidan.mp. 75. Methylphenid*.mp. 76. Methyl phenidyl acetat*.mp. 77. Methypatch.mp. 78. Metilfenidato.mp. 79. Motiron.mp. 80. MPH.mp. 81. Omozin.mp. 82. Penid.mp. 83. Phenidyl hydrochlorid*.mp. 84. Phenidylat*.mp. 85. Plimasin*.mp. 86. PMS\u2010Methylphenid*.mp. 87. Quazym.mp. 88. Richter Works.mp. 89. Riphenidat*.mp. 90. Ritalin*.mp. 91. Rubifen.mp. 92. Stimdat*.mp. 93. Tifinidat.mp. 94. Tranquilyn.mp. 95. Tsentedrin*.mp. 96. 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 97. 54 and 96 [Block A AND Block B AND Block C]  Block D Children  98. exp child/ 99. exp adolescent/ 100. exp infant/ 101. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 102. 98 or 99 or 100 or 101 103. 97 and 102 104. 103 and 97 and 102 [Block A AND Block B AND Block C AND Block D]     Adverse events search  Block 1: Methylphenidate 105. Methylphenidate.mp. or Methylphenidate/ 106. Attenta.mp. 107. Biphentin.mp. 108. Calocain.mp. 109. Centedrin*.mp. 110. Concerta.mp. 111. Daytrana.mp. 112. Dexmethylphenidat*.mp. 113. Elmifiten.mp. 114. Equasym.mp. 115. Focalin.mp. 116. Medikid.mp. 117. Medikinet.mp. 118. Meridil.mp. 119. Metadate.mp. 120. Methyl phenidat*.mp. 121. Methyl phenidylacetat*.mp. 122. Methylfenid*.mp. 123. Methylin.mp. 124. Methylofenidan.mp. 125. Methylphenid*.mp. 126. Methyl phenidyl acetat*.mp. 127. Methypatch.mp. 128. Metilfenidato.mp. 129. Motiron.mp. 130. MPH.mp. 131. Omozin.mp. 132. Penid.mp. 133. Phenidyl hydrochlorid*.mp. 134. Phenidylat*.mp. 135. Plimasin*.mp. 136. PMS\u2010Methylphenid*.mp. 137. Richter Works.mp. 138. Quazym.mp. 139. Riphenidat*.mp. 140. Ritalin*.mp. 141. Rubifen.mp. 142. Stimdat*.mp. 143. Tifinidat.mp. 144. Tranquilyn.mp. 145. Tsentedrin*.mp. 146. 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145    Block 2: Adverse events 147. (ae or co or de).fs. 148. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 149. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 150. 147 or 148 or 149    Block 3: Children 151. exp child/ 152. exp adolescent/ 153. exp infant/ 154. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 155. 151 or 152 or 153 or 154 156. exp mood disorders/ 157. (depression or depressive).ti,ab. 158. exp psychotic disorders/ 159. (psychosis or (psychotic adj4 symptom*)).ti,ab. 160. exp Body Weight/ or anorexia/ 161. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab. 162. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 163. exp Hypertension/ 164. Heart Rate/ 165. exp tachycardia/ 166. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 167. exp Death, Sudden/ 168. death.ti,ab. 169. exp Infertility/ 170. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 171. exp Carcinogens/ 172. exp neoplasms/ 173. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 174. 156 or 157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 170 or 171 or 172 or 173 175. 150 or 174 [Block 2 Adverse events] 176. 146 and 155 and 175 177. Methylphenidate/ae, po, to [Adverse Effects, Poisoning, Toxicity] 178. 155 and 177 179. 176 or 178 [Methylphenidate AND Children AND Adverse events] 180. 104 or 179 [Efficacy OR Adverse events]      Embase Ovid  Embase efficacy search  Block A : ADHD 1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14    Block B: Study design 16. randomized controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized controlled trials.mp. 19. random allocation.mp. 20. double blind method.mp. 21. single blind method.mp. 22. clinical trial.pt. 23. (clin$ adj25 trial$).ti,ab. 24. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).mp. 25. exp clinical trial/ 26. placebos.mp. 27. placebo$.ti,ab. 28. random$.ti,ab. 29. comparative study.mp. 30. evaluation studies as topic/ 31. exp clinical trials as topic/ 32. follow up studies.mp. 33. prospective studies.mp. 34. (control$ or prospectiv$ or volunteer$).ti,ab. 35. longitudinal.tw. 36. retrospective.tw. 37. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 38. exp Clinical Trials as Topic/ 39. exp Cohort Studies/ 40. exp Case\u2010Control Studies/ 41. \"case report*\".pt. 42. case control.tw. 43. (cohort adj (study or studies)).tw. 44. \"cohort analy*\".tw. 45. (observational adj (study or studies)).tw. 46. cross sectional.tw. 47. (follow up adj (study or studies)).tw. 48. (case* adj report*).tw. 49. (case* adj stud*).tw. 50. case reports.pt. 51. Cross\u2010Sectional Studies/ 52. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 53. 37 or 52 54. 15 and 53 [Block A AND Block B]    Block C: Methylphenidate 55. Methylphenidate.mp. or Methylphenidate/ 56. Attenta.mp. 57. Biphentin.mp. 58. Calocain.mp. 59. Centedrin*.mp. 60. Concerta.mp. 61. Daytrana.mp. 62. Dexmethylphenidat*.mp. 63. Equasym.mp. 64. Elmifiten.mp. 65. Focalin.mp. 66. Medikid.mp. 67. Medikinet.mp. 68. Meridil.mp. 69. Metadate.mp. 70. Methyl phenidat*.mp. 71. Methyl phenidylacetat*.mp. 72. Methylfenid*.mp. 73. Methylin.mp. 74. Methylofenidan.mp. 75. Methylphenid*.mp. 76. Methyl phenidyl acetat*.mp. 77. Methypatch.mp. 78. Metilfenidato.mp. 79. Motiron.mp. 80. MPH.mp. 81. Omozin.mp. 82. Penid.mp. 83. Phenidyl hydrochlorid*.mp. 84. Phenidylat*.mp. 85. Plimasin*.mp. 86. PMS\u2010Methylphenid*.mp. 87. Quazym.mp. 88. Richter Works.mp. 89. Riphenidat*.mp. 90. Ritalin*.mp. 91. Rubifen.mp. 92. Stimdat*.mp. 93. Tifinidat.mp. 94. Tranquilyn.mp. 95. Tsentedrin*.mp. 96. 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 97. 54 and 96 [Block A AND Block B AND Block C]    Block D: children 98. exp child/ 99. exp adolescent/ 100. exp infant/ 101. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 102. 98 or 99 or 100 or 101 103. 97 and 102 [Block A AND Block B AND Block C AND Block D] 104. 103 and 97 and 102     Adverse events search 105. Methylphenidate.mp. or Methylphenidate/ 106. Attenta.mp. 107. Biphentin.mp. 108. Calocain.mp. 109. Centedrin*.mp. 110. Concerta.mp. 111. Daytrana.mp. 112. Dexmethylphenidat*.mp. 113. Elmifiten.mp. 114. Equasym.mp. 115. Focalin.mp. 116. Medikid.mp. 117. Medikinet.mp. 118. Meridil.mp. 119. Metadate.mp. 120. Methyl phenidat*.mp. 121. Methyl phenidylacetat*.mp. 122. Methylfenid*.mp. 123. Methylin.mp. 124. Methylofenidan.mp. 125. Methylphenid*.mp. 126. Methyl phenidyl acetat*.mp. 127. Methypatch.mp. 128. Metilfenidato.mp. 129. Motiron.mp. 130. MPH.mp. 131. Omozin.mp. 132. Penid.mp. 133. Phenidyl hydrochlorid*.mp. 134. Phenidylat*.mp. 135. Plimasin*.mp. 136. PMS\u2010Methylphenid*.mp. 137. Richter Works.mp. 138. Quazym.mp. 139. Riphenidat*.mp. 140. Ritalin*.mp. 141. Rubifen.mp. 142. Stimdat*.mp. 143. Tifinidat.mp. 144. Tranquilyn.mp. 145. Tsentedrin*.mp. 146. 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 147. (ae or co or de).fs. 148. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 149. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 150. 147 or 148 or 149 151. exp child/ 152. exp adolescent/ 153. exp infant/ 154. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 155. 151 or 152 or 153 or 154 156. exp mood disorders/ 157. (depression or depressive).ti,ab. 158. exp psychotic disorders/ 159. (psychosis or (psychotic adj4 symptom*)).ti,ab. 160. exp Body Weight/ or anorexia/ 161. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab. 162. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 163. exp Hypertension/ 164. Heart Rate/ 165. exp tachycardia/ 166. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 167. exp Death, Sudden/ 168. death.ti,ab. 169. exp Infertility/ 170. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 171. exp Carcinogens/ 172. exp neoplasms/ 173. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 174. 156 or 157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 170 or 171 or 172 or 173 175. 150 or 174 176. 146 and 155 and 175 177. Methylphenidate/ae, po, to [Adverse Effects, Poisoning, Toxicity] 178. 155 and 177 179. 176 or 178 180. 104 or 179     PsycINFO Ovid  Efficacy search 1. exp attention deficit disorder/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. ADHS.ti,ab. 5. (AD adj HD).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 [Block A] 16. random$.mp. 17. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or dummy or mask$)).mp. 18. placebo$.mp. 19. crossover.mp. 20. assign$.mp. 21. allocat$.mp. 22. ((clin$ or control$ or compar$ or evaluat$ or prospectiv$) adj25 (trial$ or studi$ or study)).mp. 23. exp placebo/ 24. exp treatment effectiveness evaluation/ 25. exp mental health program evaluation/ 26. exp experimental design/ 27. versus.id. 28. vs.id. 29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 30. ((case* adj5 control*) or (case adj3 comparison*) or (case\u2010comparison or control group*)).ab,id,ti. 31. (cohort or longitudinal or prospective or retrospective).ab,id,ti. 32. (cross section* or \"prevalence study\").ab,id,ti. 33. clinical case study.md. 34. prospective study.md. 35. longitudinal study.md. 36. exp Followup Studies/ 37. followup study.md. 38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 39. 29 or 38 [Block B] 40. 15 and 39 [Block A and Block B] 41. Methylphenidate.mp. or Methylphenidate/ 42. Attenta.mp. 43. Biphentin.mp. 44. Calocain.mp. 45. Centedrin*.mp. 46. Concerta.mp. 47. Daytrana.mp. 48. Dexmethylphenidat*.mp. 49. Elmifiten.mp. 50. Equasym.mp. 51. Focalin.mp. 52. Medikid.mp. 53. Medikinet.mp. 54. Meridil.mp. 55. Metadate.mp. 56. Methyl phenidat*.mp. 57. Methyl phenidylacetat*.mp. 58. Methylfenid*.mp. 59. Methylin.mp. 60. Methylofenidan.mp. 61. Methylphenid*.mp. 62. Methyl phenidyl acetat*.mp. 63. Methypatch.mp. 64. Metilfenidato.mp. 65. Motiron.mp. 66. MPH.mp. 67. Omozin.mp. 68. Penid.mp. 69. Phenidyl hydrochlorid*.mp. 70. Phenidylat*.mp. 71. Plimasin*.mp. 72. PMS\u2010Methylphenid*.mp. 73. Quazym.mp. 74. Richter Works.mp. 75. Riphenidat*.mp. 76. Ritalin*.mp. 77. Rubifen.mp. 78. Stimdat*.mp. 79. Tifinidat.mp. 80. Tranquilyn.mp. 81. Tsentedrin*.mp. 82. 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 [Block C] 83. 40 and 82 [Block A AND Block B AND Block C] 84. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 85. 83 and 84 [Block A AND Block B AND Block C AND Block D]    Adverse events search 86. Methylphenidate.mp. or Methylphenidate/ 87. Attenta.mp. 88. Biphentin.mp. 89. Calocain.mp. 90. Centedrin*.mp. 91. Concerta.mp. 92. Daytrana.mp. 93. Dexmethylphenidat*.mp. 94. Elmifiten.mp. 95. Equasym.mp. 96. Focalin.mp. 97. Medikid.mp. 98. Medikinet.mp. 99. Meridil.mp. 100. Metadate.mp. 101. Methyl phenidat*.mp. 102. Methyl phenidylacetat*.mp. 103. Methylfenid*.mp. 104. Methylin.mp. 105. Methylofenidan.mp. 106. Methylphenid*.mp. 107. Methyl phenidyl acetat*.mp. 108. Methypatch.mp. 109. Metilfenidato.mp. 110. Motiron.mp. 111. MPH.mp. 112. Omozin.mp. 113. Penid.mp. 114. Phenidyl hydrochlorid*.mp. 115. Phenidylat*.mp. 116. Plimasin*.mp. 117. PMS\u2010Methylphenid*.mp. 118. Quazym.mp. 119. Richter Works.mp. 120. Riphenidat*.mp. 121. Ritalin*.mp. 122. Rubifen.mp. 123. Stimdat*.mp. 124. Tifinidat.mp. 125. Tranquilyn.mp. 126. Tsentedrin*.mp. 127. 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 [Block 1] 128. \"Side effects (Drug)\"/ 129. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 130. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 131. 128 or 129 or 130 132. exp major depression/ or affective disorders/ 133. (depression or depressive).ti,ab. 134. exp psychosis/ 135. (psychosis or (psychotic adj4 symptom*)).ti,ab. 136. exp body weight/ 137. exp appetite depressing drugs/ 138. Appetite/ 139. ((loss or lose or losing or decreas* or reduc*) adj3 (weight or appetite)).ti,ab. 140. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 141. exp appetite depressing drugs/ 142. Appetite/ 143. exp cardiovascular disorders/ 144. exp heart rate affecting drugs/ 145. Heart rate/ 146. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 147. \"death and dying\"/ 148. death.ti,ab. 149. exp infertility/ 150. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 151. exp neoplasms/ 152. Carcinogens/ 153. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 154. 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 or 153 155. 131 or 154 [Block 2] 156. 127 and 155 [Block 1 AND Block 2] 157. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp.[Block 3] 158. 156 and 157 [Block 1 AND Block 2 AND Block 3] 159. 85 or 158 [Efficacy OR Adverse events]     CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature) #1 MeSH descriptor: [Methylphenidate] explode all trees #2 Methylphenidate #3 Attenta #4 Biphentin #5 Calocain #6 Centedrin* #7 Concerta #8 Daytrana #9 Dexmethylphenidat* #10 Equasym #11 Focalin #12 Medikinet #13 Meridil #14 Metadate #15 Methyl phenidat* #16 Methyl phenidylacetat* #17 Methylfenid* #18 Methylin #19 Methylofenidan #20 Methylphenid* #21 Methyl phenidyl acetat* #22 Methypatch #23 Metilfenidato #24 Motiron #25 MPH #26 Penid #27 Phenidyl hydrochlorid* #28 Phenidylat* #29 Plimasin* #30 PMS\u2010Methylphenid* #31 Richter Works #32 Riphenidat* #33 Ritalin* #34 Rubifen #35 Stimdat* #36 Tsentedrin* #37 MeSH descriptor: [Child] explode all trees #38 MeSH descriptor: [Adolescent] explode all trees #39 MeSH descriptor: [Infant] explode all trees #40 (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*) #41 elmifiten or medikid or Omozin or Quazym or Tifinidat or Tranquilyn #42 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #41 #43 #37 or #38 or #39 or #40 #44 #42 and #43 #45 MeSH descriptor: [Attention Deficit and Disruptive Behavior Disorders] explode all trees #46 ADHD:ti,ab,kw #47 ADDH:ti,ab,kw #48 (ADHS):ti,ab,kw #49 (\"AD/HD\"):ti,ab,kw #50 ((attention* or behav*) near/3 (defic* or dysfunc* or disorder*)):ti,ab,kw #51 (impulsiv* or inattentiv* or inattention*):ti,ab,kw #52 ((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*)):ti,ab,kw #53 MeSH descriptor: [Hyperkinesis] explode all trees #54 (hyperkine*):ti,ab,kw #55 (minimal near/3 brain near/3 (disorder* or dysfunct* or damage*)):ti,ab,kw #56 (hyperactiv*):ti,ab,kw #57 #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 #58 #44 and #57    Conference Proceedings Citation Index \u2010 Science (CPCI\u2010S); Conference Proceedings Citation Index \u2010 Social Science & Humanities (CPCI\u2010SSH) Web of Science  #3 #2 AND #1 Databases=CPCI\u2010S, CPCI\u2010SSH  #2 TS=(child* or boy* or girl* or adolescen* or teen* orpreschool* or \"pre school*\" or infant* or baby or babies or toddler*or \"school child*\" or schoolchild* or youth*) Databases=CPCI\u2010S, CPCI\u2010SSH  #1 TS=(Methylphenidate or Attenta or Biphentin or Calocain orCentedrin* or Concerta or Daytrana or Dexmethylphenidat* orElmifiten or Equasym or Focalin or Medikid or Medikinet or Meridilor Metadate or \"Methyl phenidat*\" or \"Methyl phenidylacetat\" or Methylfenid or Methylin or Methylofenidan or Methylphenid* or \"Methyl phenidyl acetat*\" or Methypatch or Metilfenidato or Motironor MPH or Penid or Omozin or Quazym or \"Phenidyl hydrochlorid*\" orPhenidylat* or Plimasin* or \"PMS\u2010Methylphenid* \" or \"Richter Works\"or Riphenidat* or Ritalin* or Rubifen or Stimdat* or Tifinidat orTranquilyn or Tsentedrin*) Databases=CPCI\u2010S, CPCI\u2010SSH    NDLTD Theses Resources (ndltd.org/resources) methylphenidate AND child* AND (attention deficit or hyperactiv*)   TROVE \u2010 National Library of Australia (trove.nla.gov.au) methylphenidate AND child* AND (attention OR hyperactiv*)   British Library E\u2010Theses Online Service (EThOS; ethos.bl.uk) methylphenidate AND children AND attention deficit / methylphenidate AND child AND hyperactivity    Deutsche Nationalbibliothek Dissertations (www.dnb.de/EN/Home/home_node.html) methylphenidate   Open Access Theses and Dissertations (OATD; oatd.org) methylphenidate AND child* AND (attention deficit OR hyperactiv*)   Theses Collection Wales \u2010 The National Library of Wales (www.llgc.org.uk/en/discover/nlw\u2010resources/theses\u2010collection\u2010wales) methylphenidate AND child* AND (attention deficit OR hyperactiv*)   DART\u2010Europe E\u2010Theses Portal (www.dart\u2010europe.eu/basic\u2010search.php) methylphenidate AND child*   Bielefeld Academic Search Engine (BASE; www.base\u2010search.net/about/en) methylphenidate AND adhd/attention deficit/hyperactive*   Theses France (www.theses.fr/en) methylphenidate   ProQuest Open Access Dissertations (PQDT Open; pqdtopen.proquest.com/search.html) methylphenidate AND children AND adhd   ClinicalTrials.gov (clinicaltrials.gov) attention deficit or adhd or hyperactivity [Conditions] | methylphenidate [Interventions] | Child    World Health Organization International Clinical Trials Registry (WHO ICTRP; who.int/ictrp/en) Methylphenidate AND adhd OR attention OR hyperactiv*",
        "Cochrane Central Register of Controlled Trials (Central) in the Cochrane Library": "#1 MeSH descriptor: [Methylphenidate] explode all trees #2 Methylphenidate #3 Attenta #4 Biphentin #5 Calocain #6 Centedrin* #7 Concerta #8 Daytrana #9 Dexmethylphenidat* #10 Equasym #11 Focalin #12 Medikinet #13 Meridil #14 Metadate #15 Methyl phenidat* #16 Methyl phenidylacetat* #17 Methylfenid* #18 Methylin #19 Methylofenidan #20 Methylphenid* #21 Methyl phenidyl acetat* #22 Methypatch #23 Metilfenidato #24 Motiron #25 MPH #26 Penid #27 Phenidyl hydrochlorid* #28 Phenidylat* #29 Plimasin* #30 PMS\u2010Methylphenid* #31 Richter Works #32 Riphenidat* #33 Ritalin* #34 Rubifen #35 Stimdat* #36 Tsentedrin* #37 MeSH descriptor: [Child] explode all trees #38 MeSH descriptor: [Adolescent] explode all trees #39 MeSH descriptor: [Infant] explode all trees #40 (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*) #41 elmifiten or medikid or Omozin or Quazym or Tifinidat or Tranquilyn #42 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #41 #43 #37 or #38 or #39 or #40 #44 #42 and #43 #45 MeSH descriptor: [Attention Deficit and Disruptive Behavior Disorders] explode all trees #46 ADHD:ti,ab,kw #47 ADDH:ti,ab,kw #48 (ADHS):ti,ab,kw #49 (\"AD/HD\"):ti,ab,kw #50 ((attention* or behav*) near/3 (defic* or dysfunc* or disorder*)):ti,ab,kw #51 (impulsiv* or inattentiv* or inattention*):ti,ab,kw #52 ((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*)):ti,ab,kw #53 MeSH descriptor: [Hyperkinesis] explode all trees #54 (hyperkine*):ti,ab,kw #55 (minimal near/3 brain near/3 (disorder* or dysfunct* or damage*)):ti,ab,kw #56 (hyperactiv*):ti,ab,kw #57 #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 #58 #44 and #57",
        "MEDLINE Ovid": "Efficacy search  Block A: ADHD 1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14    Block B: Study design 16. randomized controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized controlled trials.mp. 19. random allocation.mp. 20. double blind method.mp. 21. single blind method.mp. 22. clinical trial.pt. 23. (clin$ adj25 trial$).ti,ab. 24. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).mp. 25. exp clinical trial/ 26. placebos.mp. 27. placebo$.ti,ab. 28. random$.ti,ab. 29. comparative study.mp. 30. evaluation studies as topic/ 31. exp clinical trials as topic/ 32. follow up studies.mp. 33. prospective studies.mp. 34. (control$ or prospectiv$ or volunteer$).ti,ab. 35. longitudinal.tw. 36. retrospective.tw. 37. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 38. exp Clinical Trials as Topic/ 39. exp Cohort Studies/ 40. exp Case\u2010Control Studies/ 41. \"case report*\".pt. 42. case control.tw. 43. (cohort adj (study or studies)).tw. 44. \"cohort analy*\".tw. 45. (observational adj (study or studies)).tw. 46. cross sectional.tw. 47. (follow up adj (study or studies)).tw. 48. (case* adj report*).tw. 49. (case* adj stud*).tw. 50. case reports.pt. 51. Cross\u2010Sectional Studies/ 52. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 53. 37 or 52 54. 15 and 53 [Block A AND Block B]    Block C: Methylphenidate 55. Methylphenidate.mp. or Methylphenidate/ 56. Attenta.mp. 57. Biphentin.mp. 58. Calocain.mp. 59. Centedrin*.mp. 60. Concerta.mp. 61. Daytrana.mp. 62. Dexmethylphenidat*.mp. 63. Equasym.mp. 64. Elmifiten.mp. 65. Focalin.mp. 66. Medikid.mp. 67. Medikinet.mp. 68. Meridil.mp. 69. Metadate.mp. 70. Methyl phenidat*.mp. 71. Methyl phenidylacetat*.mp. 72. Methylfenid*.mp. 73. Methylin.mp. 74. Methylofenidan.mp. 75. Methylphenid*.mp. 76. Methyl phenidyl acetat*.mp. 77. Methypatch.mp. 78. Metilfenidato.mp. 79. Motiron.mp. 80. MPH.mp. 81. Omozin.mp. 82. Penid.mp. 83. Phenidyl hydrochlorid*.mp. 84. Phenidylat*.mp. 85. Plimasin*.mp. 86. PMS\u2010Methylphenid*.mp. 87. Quazym.mp. 88. Richter Works.mp. 89. Riphenidat*.mp. 90. Ritalin*.mp. 91. Rubifen.mp. 92. Stimdat*.mp. 93. Tifinidat.mp. 94. Tranquilyn.mp. 95. Tsentedrin*.mp. 96. 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 97. 54 and 96 [Block A AND Block B AND Block C]  Block D Children  98. exp child/ 99. exp adolescent/ 100. exp infant/ 101. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 102. 98 or 99 or 100 or 101 103. 97 and 102 104. 103 and 97 and 102 [Block A AND Block B AND Block C AND Block D]     Adverse events search  Block 1: Methylphenidate 105. Methylphenidate.mp. or Methylphenidate/ 106. Attenta.mp. 107. Biphentin.mp. 108. Calocain.mp. 109. Centedrin*.mp. 110. Concerta.mp. 111. Daytrana.mp. 112. Dexmethylphenidat*.mp. 113. Elmifiten.mp. 114. Equasym.mp. 115. Focalin.mp. 116. Medikid.mp. 117. Medikinet.mp. 118. Meridil.mp. 119. Metadate.mp. 120. Methyl phenidat*.mp. 121. Methyl phenidylacetat*.mp. 122. Methylfenid*.mp. 123. Methylin.mp. 124. Methylofenidan.mp. 125. Methylphenid*.mp. 126. Methyl phenidyl acetat*.mp. 127. Methypatch.mp. 128. Metilfenidato.mp. 129. Motiron.mp. 130. MPH.mp. 131. Omozin.mp. 132. Penid.mp. 133. Phenidyl hydrochlorid*.mp. 134. Phenidylat*.mp. 135. Plimasin*.mp. 136. PMS\u2010Methylphenid*.mp. 137. Richter Works.mp. 138. Quazym.mp. 139. Riphenidat*.mp. 140. Ritalin*.mp. 141. Rubifen.mp. 142. Stimdat*.mp. 143. Tifinidat.mp. 144. Tranquilyn.mp. 145. Tsentedrin*.mp. 146. 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145    Block 2: Adverse events 147. (ae or co or de).fs. 148. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 149. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 150. 147 or 148 or 149    Block 3: Children 151. exp child/ 152. exp adolescent/ 153. exp infant/ 154. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 155. 151 or 152 or 153 or 154 156. exp mood disorders/ 157. (depression or depressive).ti,ab. 158. exp psychotic disorders/ 159. (psychosis or (psychotic adj4 symptom*)).ti,ab. 160. exp Body Weight/ or anorexia/ 161. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab. 162. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 163. exp Hypertension/ 164. Heart Rate/ 165. exp tachycardia/ 166. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 167. exp Death, Sudden/ 168. death.ti,ab. 169. exp Infertility/ 170. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 171. exp Carcinogens/ 172. exp neoplasms/ 173. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 174. 156 or 157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 170 or 171 or 172 or 173 175. 150 or 174 [Block 2 Adverse events] 176. 146 and 155 and 175 177. Methylphenidate/ae, po, to [Adverse Effects, Poisoning, Toxicity] 178. 155 and 177 179. 176 or 178 [Methylphenidate AND Children AND Adverse events] 180. 104 or 179 [Efficacy OR Adverse events]",
        "Efficacy search": "1. exp attention deficit disorder/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. ADHS.ti,ab. 5. (AD adj HD).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 [Block A] 16. random$.mp. 17. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or dummy or mask$)).mp. 18. placebo$.mp. 19. crossover.mp. 20. assign$.mp. 21. allocat$.mp. 22. ((clin$ or control$ or compar$ or evaluat$ or prospectiv$) adj25 (trial$ or studi$ or study)).mp. 23. exp placebo/ 24. exp treatment effectiveness evaluation/ 25. exp mental health program evaluation/ 26. exp experimental design/ 27. versus.id. 28. vs.id. 29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 30. ((case* adj5 control*) or (case adj3 comparison*) or (case\u2010comparison or control group*)).ab,id,ti. 31. (cohort or longitudinal or prospective or retrospective).ab,id,ti. 32. (cross section* or \"prevalence study\").ab,id,ti. 33. clinical case study.md. 34. prospective study.md. 35. longitudinal study.md. 36. exp Followup Studies/ 37. followup study.md. 38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 39. 29 or 38 [Block B] 40. 15 and 39 [Block A and Block B] 41. Methylphenidate.mp. or Methylphenidate/ 42. Attenta.mp. 43. Biphentin.mp. 44. Calocain.mp. 45. Centedrin*.mp. 46. Concerta.mp. 47. Daytrana.mp. 48. Dexmethylphenidat*.mp. 49. Elmifiten.mp. 50. Equasym.mp. 51. Focalin.mp. 52. Medikid.mp. 53. Medikinet.mp. 54. Meridil.mp. 55. Metadate.mp. 56. Methyl phenidat*.mp. 57. Methyl phenidylacetat*.mp. 58. Methylfenid*.mp. 59. Methylin.mp. 60. Methylofenidan.mp. 61. Methylphenid*.mp. 62. Methyl phenidyl acetat*.mp. 63. Methypatch.mp. 64. Metilfenidato.mp. 65. Motiron.mp. 66. MPH.mp. 67. Omozin.mp. 68. Penid.mp. 69. Phenidyl hydrochlorid*.mp. 70. Phenidylat*.mp. 71. Plimasin*.mp. 72. PMS\u2010Methylphenid*.mp. 73. Quazym.mp. 74. Richter Works.mp. 75. Riphenidat*.mp. 76. Ritalin*.mp. 77. Rubifen.mp. 78. Stimdat*.mp. 79. Tifinidat.mp. 80. Tranquilyn.mp. 81. Tsentedrin*.mp. 82. 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 [Block C] 83. 40 and 82 [Block A AND Block B AND Block C] 84. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 85. 83 and 84 [Block A AND Block B AND Block C AND Block D]",
        "Block A: ADHD": "1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14",
        "Block B: Study design": "16. randomized controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized controlled trials.mp. 19. random allocation.mp. 20. double blind method.mp. 21. single blind method.mp. 22. clinical trial.pt. 23. (clin$ adj25 trial$).ti,ab. 24. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).mp. 25. exp clinical trial/ 26. placebos.mp. 27. placebo$.ti,ab. 28. random$.ti,ab. 29. comparative study.mp. 30. evaluation studies as topic/ 31. exp clinical trials as topic/ 32. follow up studies.mp. 33. prospective studies.mp. 34. (control$ or prospectiv$ or volunteer$).ti,ab. 35. longitudinal.tw. 36. retrospective.tw. 37. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 38. exp Clinical Trials as Topic/ 39. exp Cohort Studies/ 40. exp Case\u2010Control Studies/ 41. \"case report*\".pt. 42. case control.tw. 43. (cohort adj (study or studies)).tw. 44. \"cohort analy*\".tw. 45. (observational adj (study or studies)).tw. 46. cross sectional.tw. 47. (follow up adj (study or studies)).tw. 48. (case* adj report*).tw. 49. (case* adj stud*).tw. 50. case reports.pt. 51. Cross\u2010Sectional Studies/ 52. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 53. 37 or 52 54. 15 and 53 [Block A AND Block B]",
        "Block C: Methylphenidate": "55. Methylphenidate.mp. or Methylphenidate/ 56. Attenta.mp. 57. Biphentin.mp. 58. Calocain.mp. 59. Centedrin*.mp. 60. Concerta.mp. 61. Daytrana.mp. 62. Dexmethylphenidat*.mp. 63. Equasym.mp. 64. Elmifiten.mp. 65. Focalin.mp. 66. Medikid.mp. 67. Medikinet.mp. 68. Meridil.mp. 69. Metadate.mp. 70. Methyl phenidat*.mp. 71. Methyl phenidylacetat*.mp. 72. Methylfenid*.mp. 73. Methylin.mp. 74. Methylofenidan.mp. 75. Methylphenid*.mp. 76. Methyl phenidyl acetat*.mp. 77. Methypatch.mp. 78. Metilfenidato.mp. 79. Motiron.mp. 80. MPH.mp. 81. Omozin.mp. 82. Penid.mp. 83. Phenidyl hydrochlorid*.mp. 84. Phenidylat*.mp. 85. Plimasin*.mp. 86. PMS\u2010Methylphenid*.mp. 87. Quazym.mp. 88. Richter Works.mp. 89. Riphenidat*.mp. 90. Ritalin*.mp. 91. Rubifen.mp. 92. Stimdat*.mp. 93. Tifinidat.mp. 94. Tranquilyn.mp. 95. Tsentedrin*.mp. 96. 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 97. 54 and 96 [Block A AND Block B AND Block C]",
        "Adverse events search": "86. Methylphenidate.mp. or Methylphenidate/ 87. Attenta.mp. 88. Biphentin.mp. 89. Calocain.mp. 90. Centedrin*.mp. 91. Concerta.mp. 92. Daytrana.mp. 93. Dexmethylphenidat*.mp. 94. Elmifiten.mp. 95. Equasym.mp. 96. Focalin.mp. 97. Medikid.mp. 98. Medikinet.mp. 99. Meridil.mp. 100. Metadate.mp. 101. Methyl phenidat*.mp. 102. Methyl phenidylacetat*.mp. 103. Methylfenid*.mp. 104. Methylin.mp. 105. Methylofenidan.mp. 106. Methylphenid*.mp. 107. Methyl phenidyl acetat*.mp. 108. Methypatch.mp. 109. Metilfenidato.mp. 110. Motiron.mp. 111. MPH.mp. 112. Omozin.mp. 113. Penid.mp. 114. Phenidyl hydrochlorid*.mp. 115. Phenidylat*.mp. 116. Plimasin*.mp. 117. PMS\u2010Methylphenid*.mp. 118. Quazym.mp. 119. Richter Works.mp. 120. Riphenidat*.mp. 121. Ritalin*.mp. 122. Rubifen.mp. 123. Stimdat*.mp. 124. Tifinidat.mp. 125. Tranquilyn.mp. 126. Tsentedrin*.mp. 127. 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 [Block 1] 128. \"Side effects (Drug)\"/ 129. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 130. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 131. 128 or 129 or 130 132. exp major depression/ or affective disorders/ 133. (depression or depressive).ti,ab. 134. exp psychosis/ 135. (psychosis or (psychotic adj4 symptom*)).ti,ab. 136. exp body weight/ 137. exp appetite depressing drugs/ 138. Appetite/ 139. ((loss or lose or losing or decreas* or reduc*) adj3 (weight or appetite)).ti,ab. 140. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 141. exp appetite depressing drugs/ 142. Appetite/ 143. exp cardiovascular disorders/ 144. exp heart rate affecting drugs/ 145. Heart rate/ 146. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 147. \"death and dying\"/ 148. death.ti,ab. 149. exp infertility/ 150. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 151. exp neoplasms/ 152. Carcinogens/ 153. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 154. 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 or 153 155. 131 or 154 [Block 2] 156. 127 and 155 [Block 1 AND Block 2] 157. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp.[Block 3] 158. 156 and 157 [Block 1 AND Block 2 AND Block 3] 159. 85 or 158 [Efficacy OR Adverse events]",
        "Block 1: Methylphenidate": "105. Methylphenidate.mp. or Methylphenidate/ 106. Attenta.mp. 107. Biphentin.mp. 108. Calocain.mp. 109. Centedrin*.mp. 110. Concerta.mp. 111. Daytrana.mp. 112. Dexmethylphenidat*.mp. 113. Elmifiten.mp. 114. Equasym.mp. 115. Focalin.mp. 116. Medikid.mp. 117. Medikinet.mp. 118. Meridil.mp. 119. Metadate.mp. 120. Methyl phenidat*.mp. 121. Methyl phenidylacetat*.mp. 122. Methylfenid*.mp. 123. Methylin.mp. 124. Methylofenidan.mp. 125. Methylphenid*.mp. 126. Methyl phenidyl acetat*.mp. 127. Methypatch.mp. 128. Metilfenidato.mp. 129. Motiron.mp. 130. MPH.mp. 131. Omozin.mp. 132. Penid.mp. 133. Phenidyl hydrochlorid*.mp. 134. Phenidylat*.mp. 135. Plimasin*.mp. 136. PMS\u2010Methylphenid*.mp. 137. Richter Works.mp. 138. Quazym.mp. 139. Riphenidat*.mp. 140. Ritalin*.mp. 141. Rubifen.mp. 142. Stimdat*.mp. 143. Tifinidat.mp. 144. Tranquilyn.mp. 145. Tsentedrin*.mp. 146. 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145",
        "Block 2: Adverse events": "147. (ae or co or de).fs. 148. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 149. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 150. 147 or 148 or 149",
        "Block 3: Children": "151. exp child/ 152. exp adolescent/ 153. exp infant/ 154. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 155. 151 or 152 or 153 or 154 156. exp mood disorders/ 157. (depression or depressive).ti,ab. 158. exp psychotic disorders/ 159. (psychosis or (psychotic adj4 symptom*)).ti,ab. 160. exp Body Weight/ or anorexia/ 161. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab. 162. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 163. exp Hypertension/ 164. Heart Rate/ 165. exp tachycardia/ 166. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 167. exp Death, Sudden/ 168. death.ti,ab. 169. exp Infertility/ 170. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 171. exp Carcinogens/ 172. exp neoplasms/ 173. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 174. 156 or 157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 170 or 171 or 172 or 173 175. 150 or 174 [Block 2 Adverse events] 176. 146 and 155 and 175 177. Methylphenidate/ae, po, to [Adverse Effects, Poisoning, Toxicity] 178. 155 and 177 179. 176 or 178 [Methylphenidate AND Children AND Adverse events] 180. 104 or 179 [Efficacy OR Adverse events]",
        "Embase Ovid": "Embase efficacy search  Block A : ADHD 1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14    Block B: Study design 16. randomized controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized controlled trials.mp. 19. random allocation.mp. 20. double blind method.mp. 21. single blind method.mp. 22. clinical trial.pt. 23. (clin$ adj25 trial$).ti,ab. 24. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).mp. 25. exp clinical trial/ 26. placebos.mp. 27. placebo$.ti,ab. 28. random$.ti,ab. 29. comparative study.mp. 30. evaluation studies as topic/ 31. exp clinical trials as topic/ 32. follow up studies.mp. 33. prospective studies.mp. 34. (control$ or prospectiv$ or volunteer$).ti,ab. 35. longitudinal.tw. 36. retrospective.tw. 37. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 38. exp Clinical Trials as Topic/ 39. exp Cohort Studies/ 40. exp Case\u2010Control Studies/ 41. \"case report*\".pt. 42. case control.tw. 43. (cohort adj (study or studies)).tw. 44. \"cohort analy*\".tw. 45. (observational adj (study or studies)).tw. 46. cross sectional.tw. 47. (follow up adj (study or studies)).tw. 48. (case* adj report*).tw. 49. (case* adj stud*).tw. 50. case reports.pt. 51. Cross\u2010Sectional Studies/ 52. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 53. 37 or 52 54. 15 and 53 [Block A AND Block B]    Block C: Methylphenidate 55. Methylphenidate.mp. or Methylphenidate/ 56. Attenta.mp. 57. Biphentin.mp. 58. Calocain.mp. 59. Centedrin*.mp. 60. Concerta.mp. 61. Daytrana.mp. 62. Dexmethylphenidat*.mp. 63. Equasym.mp. 64. Elmifiten.mp. 65. Focalin.mp. 66. Medikid.mp. 67. Medikinet.mp. 68. Meridil.mp. 69. Metadate.mp. 70. Methyl phenidat*.mp. 71. Methyl phenidylacetat*.mp. 72. Methylfenid*.mp. 73. Methylin.mp. 74. Methylofenidan.mp. 75. Methylphenid*.mp. 76. Methyl phenidyl acetat*.mp. 77. Methypatch.mp. 78. Metilfenidato.mp. 79. Motiron.mp. 80. MPH.mp. 81. Omozin.mp. 82. Penid.mp. 83. Phenidyl hydrochlorid*.mp. 84. Phenidylat*.mp. 85. Plimasin*.mp. 86. PMS\u2010Methylphenid*.mp. 87. Quazym.mp. 88. Richter Works.mp. 89. Riphenidat*.mp. 90. Ritalin*.mp. 91. Rubifen.mp. 92. Stimdat*.mp. 93. Tifinidat.mp. 94. Tranquilyn.mp. 95. Tsentedrin*.mp. 96. 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 97. 54 and 96 [Block A AND Block B AND Block C]    Block D: children 98. exp child/ 99. exp adolescent/ 100. exp infant/ 101. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 102. 98 or 99 or 100 or 101 103. 97 and 102 [Block A AND Block B AND Block C AND Block D] 104. 103 and 97 and 102     Adverse events search 105. Methylphenidate.mp. or Methylphenidate/ 106. Attenta.mp. 107. Biphentin.mp. 108. Calocain.mp. 109. Centedrin*.mp. 110. Concerta.mp. 111. Daytrana.mp. 112. Dexmethylphenidat*.mp. 113. Elmifiten.mp. 114. Equasym.mp. 115. Focalin.mp. 116. Medikid.mp. 117. Medikinet.mp. 118. Meridil.mp. 119. Metadate.mp. 120. Methyl phenidat*.mp. 121. Methyl phenidylacetat*.mp. 122. Methylfenid*.mp. 123. Methylin.mp. 124. Methylofenidan.mp. 125. Methylphenid*.mp. 126. Methyl phenidyl acetat*.mp. 127. Methypatch.mp. 128. Metilfenidato.mp. 129. Motiron.mp. 130. MPH.mp. 131. Omozin.mp. 132. Penid.mp. 133. Phenidyl hydrochlorid*.mp. 134. Phenidylat*.mp. 135. Plimasin*.mp. 136. PMS\u2010Methylphenid*.mp. 137. Richter Works.mp. 138. Quazym.mp. 139. Riphenidat*.mp. 140. Ritalin*.mp. 141. Rubifen.mp. 142. Stimdat*.mp. 143. Tifinidat.mp. 144. Tranquilyn.mp. 145. Tsentedrin*.mp. 146. 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 147. (ae or co or de).fs. 148. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 149. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 150. 147 or 148 or 149 151. exp child/ 152. exp adolescent/ 153. exp infant/ 154. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 155. 151 or 152 or 153 or 154 156. exp mood disorders/ 157. (depression or depressive).ti,ab. 158. exp psychotic disorders/ 159. (psychosis or (psychotic adj4 symptom*)).ti,ab. 160. exp Body Weight/ or anorexia/ 161. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab. 162. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 163. exp Hypertension/ 164. Heart Rate/ 165. exp tachycardia/ 166. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 167. exp Death, Sudden/ 168. death.ti,ab. 169. exp Infertility/ 170. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 171. exp Carcinogens/ 172. exp neoplasms/ 173. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 174. 156 or 157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 170 or 171 or 172 or 173 175. 150 or 174 176. 146 and 155 and 175 177. Methylphenidate/ae, po, to [Adverse Effects, Poisoning, Toxicity] 178. 155 and 177 179. 176 or 178 180. 104 or 179",
        "Embase efficacy search": "Block A : ADHD 1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14    Block B: Study design 16. randomized controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized controlled trials.mp. 19. random allocation.mp. 20. double blind method.mp. 21. single blind method.mp. 22. clinical trial.pt. 23. (clin$ adj25 trial$).ti,ab. 24. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).mp. 25. exp clinical trial/ 26. placebos.mp. 27. placebo$.ti,ab. 28. random$.ti,ab. 29. comparative study.mp. 30. evaluation studies as topic/ 31. exp clinical trials as topic/ 32. follow up studies.mp. 33. prospective studies.mp. 34. (control$ or prospectiv$ or volunteer$).ti,ab. 35. longitudinal.tw. 36. retrospective.tw. 37. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 38. exp Clinical Trials as Topic/ 39. exp Cohort Studies/ 40. exp Case\u2010Control Studies/ 41. \"case report*\".pt. 42. case control.tw. 43. (cohort adj (study or studies)).tw. 44. \"cohort analy*\".tw. 45. (observational adj (study or studies)).tw. 46. cross sectional.tw. 47. (follow up adj (study or studies)).tw. 48. (case* adj report*).tw. 49. (case* adj stud*).tw. 50. case reports.pt. 51. Cross\u2010Sectional Studies/ 52. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 53. 37 or 52 54. 15 and 53 [Block A AND Block B]    Block C: Methylphenidate 55. Methylphenidate.mp. or Methylphenidate/ 56. Attenta.mp. 57. Biphentin.mp. 58. Calocain.mp. 59. Centedrin*.mp. 60. Concerta.mp. 61. Daytrana.mp. 62. Dexmethylphenidat*.mp. 63. Equasym.mp. 64. Elmifiten.mp. 65. Focalin.mp. 66. Medikid.mp. 67. Medikinet.mp. 68. Meridil.mp. 69. Metadate.mp. 70. Methyl phenidat*.mp. 71. Methyl phenidylacetat*.mp. 72. Methylfenid*.mp. 73. Methylin.mp. 74. Methylofenidan.mp. 75. Methylphenid*.mp. 76. Methyl phenidyl acetat*.mp. 77. Methypatch.mp. 78. Metilfenidato.mp. 79. Motiron.mp. 80. MPH.mp. 81. Omozin.mp. 82. Penid.mp. 83. Phenidyl hydrochlorid*.mp. 84. Phenidylat*.mp. 85. Plimasin*.mp. 86. PMS\u2010Methylphenid*.mp. 87. Quazym.mp. 88. Richter Works.mp. 89. Riphenidat*.mp. 90. Ritalin*.mp. 91. Rubifen.mp. 92. Stimdat*.mp. 93. Tifinidat.mp. 94. Tranquilyn.mp. 95. Tsentedrin*.mp. 96. 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 97. 54 and 96 [Block A AND Block B AND Block C]    Block D: children 98. exp child/ 99. exp adolescent/ 100. exp infant/ 101. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 102. 98 or 99 or 100 or 101 103. 97 and 102 [Block A AND Block B AND Block C AND Block D] 104. 103 and 97 and 102",
        "Block A : ADHD": "1. exp \"Attention Deficit and Disruptive Behavior Disorders\"/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. adhs.ti,ab. 5. (ad adj hd).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14",
        "Block D: children": "98. exp child/ 99. exp adolescent/ 100. exp infant/ 101. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 102. 98 or 99 or 100 or 101 103. 97 and 102 [Block A AND Block B AND Block C AND Block D] 104. 103 and 97 and 102",
        "PsycINFO Ovid": "Efficacy search 1. exp attention deficit disorder/ 2. adhd.ti,ab. 3. addh.ti,ab. 4. ADHS.ti,ab. 5. (AD adj HD).ti,ab. 6. ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).ti,ab. 7. ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).ti,ab. 8. (impulsiv$ or inattentiv$ or inattention$).ti,ab. 9. hyperactiv$.ti,ab. 10. hyperkinesis$.ti,ab. 11. exp Hyperkinesis/ 12. (minimal adj brain adj3 disorder$).ti,ab. 13. (minimal adj brain adj3 dysfunction$).ti,ab. 14. (minimal adj brain adj3 damage$).ti,ab. 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 [Block A] 16. random$.mp. 17. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or dummy or mask$)).mp. 18. placebo$.mp. 19. crossover.mp. 20. assign$.mp. 21. allocat$.mp. 22. ((clin$ or control$ or compar$ or evaluat$ or prospectiv$) adj25 (trial$ or studi$ or study)).mp. 23. exp placebo/ 24. exp treatment effectiveness evaluation/ 25. exp mental health program evaluation/ 26. exp experimental design/ 27. versus.id. 28. vs.id. 29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 30. ((case* adj5 control*) or (case adj3 comparison*) or (case\u2010comparison or control group*)).ab,id,ti. 31. (cohort or longitudinal or prospective or retrospective).ab,id,ti. 32. (cross section* or \"prevalence study\").ab,id,ti. 33. clinical case study.md. 34. prospective study.md. 35. longitudinal study.md. 36. exp Followup Studies/ 37. followup study.md. 38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 39. 29 or 38 [Block B] 40. 15 and 39 [Block A and Block B] 41. Methylphenidate.mp. or Methylphenidate/ 42. Attenta.mp. 43. Biphentin.mp. 44. Calocain.mp. 45. Centedrin*.mp. 46. Concerta.mp. 47. Daytrana.mp. 48. Dexmethylphenidat*.mp. 49. Elmifiten.mp. 50. Equasym.mp. 51. Focalin.mp. 52. Medikid.mp. 53. Medikinet.mp. 54. Meridil.mp. 55. Metadate.mp. 56. Methyl phenidat*.mp. 57. Methyl phenidylacetat*.mp. 58. Methylfenid*.mp. 59. Methylin.mp. 60. Methylofenidan.mp. 61. Methylphenid*.mp. 62. Methyl phenidyl acetat*.mp. 63. Methypatch.mp. 64. Metilfenidato.mp. 65. Motiron.mp. 66. MPH.mp. 67. Omozin.mp. 68. Penid.mp. 69. Phenidyl hydrochlorid*.mp. 70. Phenidylat*.mp. 71. Plimasin*.mp. 72. PMS\u2010Methylphenid*.mp. 73. Quazym.mp. 74. Richter Works.mp. 75. Riphenidat*.mp. 76. Ritalin*.mp. 77. Rubifen.mp. 78. Stimdat*.mp. 79. Tifinidat.mp. 80. Tranquilyn.mp. 81. Tsentedrin*.mp. 82. 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 [Block C] 83. 40 and 82 [Block A AND Block B AND Block C] 84. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp. 85. 83 and 84 [Block A AND Block B AND Block C AND Block D]    Adverse events search 86. Methylphenidate.mp. or Methylphenidate/ 87. Attenta.mp. 88. Biphentin.mp. 89. Calocain.mp. 90. Centedrin*.mp. 91. Concerta.mp. 92. Daytrana.mp. 93. Dexmethylphenidat*.mp. 94. Elmifiten.mp. 95. Equasym.mp. 96. Focalin.mp. 97. Medikid.mp. 98. Medikinet.mp. 99. Meridil.mp. 100. Metadate.mp. 101. Methyl phenidat*.mp. 102. Methyl phenidylacetat*.mp. 103. Methylfenid*.mp. 104. Methylin.mp. 105. Methylofenidan.mp. 106. Methylphenid*.mp. 107. Methyl phenidyl acetat*.mp. 108. Methypatch.mp. 109. Metilfenidato.mp. 110. Motiron.mp. 111. MPH.mp. 112. Omozin.mp. 113. Penid.mp. 114. Phenidyl hydrochlorid*.mp. 115. Phenidylat*.mp. 116. Plimasin*.mp. 117. PMS\u2010Methylphenid*.mp. 118. Quazym.mp. 119. Richter Works.mp. 120. Riphenidat*.mp. 121. Ritalin*.mp. 122. Rubifen.mp. 123. Stimdat*.mp. 124. Tifinidat.mp. 125. Tranquilyn.mp. 126. Tsentedrin*.mp. 127. 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 [Block 1] 128. \"Side effects (Drug)\"/ 129. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab. 130. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. 131. 128 or 129 or 130 132. exp major depression/ or affective disorders/ 133. (depression or depressive).ti,ab. 134. exp psychosis/ 135. (psychosis or (psychotic adj4 symptom*)).ti,ab. 136. exp body weight/ 137. exp appetite depressing drugs/ 138. Appetite/ 139. ((loss or lose or losing or decreas* or reduc*) adj3 (weight or appetite)).ti,ab. 140. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab. 141. exp appetite depressing drugs/ 142. Appetite/ 143. exp cardiovascular disorders/ 144. exp heart rate affecting drugs/ 145. Heart rate/ 146. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab. 147. \"death and dying\"/ 148. death.ti,ab. 149. exp infertility/ 150. (((loss or reduc*) adj4 fertility) or infertility).ti,ab. 151. exp neoplasms/ 152. Carcinogens/ 153. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab. 154. 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 or 153 155. 131 or 154 [Block 2] 156. 127 and 155 [Block 1 AND Block 2] 157. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*).mp.[Block 3] 158. 156 and 157 [Block 1 AND Block 2 AND Block 3] 159. 85 or 158 [Efficacy OR Adverse events]",
        "CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature)": "#1 MeSH descriptor: [Methylphenidate] explode all trees #2 Methylphenidate #3 Attenta #4 Biphentin #5 Calocain #6 Centedrin* #7 Concerta #8 Daytrana #9 Dexmethylphenidat* #10 Equasym #11 Focalin #12 Medikinet #13 Meridil #14 Metadate #15 Methyl phenidat* #16 Methyl phenidylacetat* #17 Methylfenid* #18 Methylin #19 Methylofenidan #20 Methylphenid* #21 Methyl phenidyl acetat* #22 Methypatch #23 Metilfenidato #24 Motiron #25 MPH #26 Penid #27 Phenidyl hydrochlorid* #28 Phenidylat* #29 Plimasin* #30 PMS\u2010Methylphenid* #31 Richter Works #32 Riphenidat* #33 Ritalin* #34 Rubifen #35 Stimdat* #36 Tsentedrin* #37 MeSH descriptor: [Child] explode all trees #38 MeSH descriptor: [Adolescent] explode all trees #39 MeSH descriptor: [Infant] explode all trees #40 (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or toddler* or school child* or youth*) #41 elmifiten or medikid or Omozin or Quazym or Tifinidat or Tranquilyn #42 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #41 #43 #37 or #38 or #39 or #40 #44 #42 and #43 #45 MeSH descriptor: [Attention Deficit and Disruptive Behavior Disorders] explode all trees #46 ADHD:ti,ab,kw #47 ADDH:ti,ab,kw #48 (ADHS):ti,ab,kw #49 (\"AD/HD\"):ti,ab,kw #50 ((attention* or behav*) near/3 (defic* or dysfunc* or disorder*)):ti,ab,kw #51 (impulsiv* or inattentiv* or inattention*):ti,ab,kw #52 ((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*)):ti,ab,kw #53 MeSH descriptor: [Hyperkinesis] explode all trees #54 (hyperkine*):ti,ab,kw #55 (minimal near/3 brain near/3 (disorder* or dysfunct* or damage*)):ti,ab,kw #56 (hyperactiv*):ti,ab,kw #57 #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 #58 #44 and #57",
        "Conference Proceedings Citation Index \u2010 Science (CPCI\u2010S); Conference Proceedings Citation Index \u2010 Social Science & Humanities (CPCI\u2010SSH) Web of Science": "#3 #2 AND #1 Databases=CPCI\u2010S, CPCI\u2010SSH  #2 TS=(child* or boy* or girl* or adolescen* or teen* orpreschool* or \"pre school*\" or infant* or baby or babies or toddler*or \"school child*\" or schoolchild* or youth*) Databases=CPCI\u2010S, CPCI\u2010SSH  #1 TS=(Methylphenidate or Attenta or Biphentin or Calocain orCentedrin* or Concerta or Daytrana or Dexmethylphenidat* orElmifiten or Equasym or Focalin or Medikid or Medikinet or Meridilor Metadate or \"Methyl phenidat*\" or \"Methyl phenidylacetat\" or Methylfenid or Methylin or Methylofenidan or Methylphenid* or \"Methyl phenidyl acetat*\" or Methypatch or Metilfenidato or Motironor MPH or Penid or Omozin or Quazym or \"Phenidyl hydrochlorid*\" orPhenidylat* or Plimasin* or \"PMS\u2010Methylphenid* \" or \"Richter Works\"or Riphenidat* or Ritalin* or Rubifen or Stimdat* or Tifinidat orTranquilyn or Tsentedrin*) Databases=CPCI\u2010S, CPCI\u2010SSH",
        "NDLTD Theses Resources (ndltd.org/resources)": "methylphenidate AND child* AND (attention deficit or hyperactiv*)",
        "TROVE \u2010 National Library of Australia (trove.nla.gov.au)": "methylphenidate AND child* AND (attention OR hyperactiv*)",
        "British Library E\u2010Theses Online Service (EThOS; ethos.bl.uk)": "methylphenidate AND children AND attention deficit / methylphenidate AND child AND hyperactivity",
        "Deutsche Nationalbibliothek Dissertations (www.dnb.de/EN/Home/home_node.html)": "methylphenidate",
        "Open Access Theses and Dissertations (OATD; oatd.org)": "methylphenidate AND child* AND (attention deficit OR hyperactiv*)",
        "Theses Collection Wales \u2010 The National Library of Wales (www.llgc.org.uk/en/discover/nlw\u2010resources/theses\u2010collection\u2010wales)": "methylphenidate AND child* AND (attention deficit OR hyperactiv*)",
        "DART\u2010Europe E\u2010Theses Portal (www.dart\u2010europe.eu/basic\u2010search.php)": "methylphenidate AND child*",
        "Bielefeld Academic Search Engine (BASE; www.base\u2010search.net/about/en)": "methylphenidate AND adhd/attention deficit/hyperactive*",
        "Theses France (www.theses.fr/en)": "methylphenidate",
        "ProQuest Open Access Dissertations (PQDT Open; pqdtopen.proquest.com/search.html)": "methylphenidate AND children AND adhd",
        "ClinicalTrials.gov (clinicaltrials.gov)": "attention deficit or adhd or hyperactivity [Conditions] | methylphenidate [Interventions] | Child",
        "World Health Organization International Clinical Trials Registry (WHO ICTRP; who.int/ictrp/en)": "Methylphenidate AND adhd OR attention OR hyperactiv*"
    }
}